# Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06752811/  
OnCo record `nct06752811` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Yizhong Pharmaceutical Co., Ltd., now recruiting.

## Summary

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT06752811 by Shanghai Yizhong Pharmaceutical Co., Ltd., with 416 participants planned, started 2025-02-05 and due to reach its primary completion in 2027-07-01. Interventions recorded: paclitaxel polymeric micelles for injection, Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (albumin bound ).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06752811
- Phase: 3
- Setting: A Multi-center, Randomized, Open, Parallel-group, Positive Drug-controlled Phase III Clinical Trial for Evaluating the Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Plus Gemcitabine and Paclitaxel for Injection (Albumin-bound) Plus Gemcitabine for Injection in the First-line Treatment of Metastatic Pancreatic Cancer
- Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd.
- Enrolled: 416

## Sources

- ClinicalTrials.gov NCT06752811: https://clinicaltrials.gov/study/NCT06752811

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06752811.json